NCT00003816 arm group 29b25f7019ae500fe2ed6713b46b570d [clinicaltrials_resource:NCT00003816/arm-group/29b25f7019ae500fe2ed6713b46b570d]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00003816 arm group 29b25f7019ae500fe2ed6713b46b570d [clinicaltrials_resource:NCT00003816/arm-group/29b25f7019ae500fe2ed6713b46b570d]
Bio2RDF identifier
NCT00003816/arm-group/29b25f7019ae500fe2ed6713b46b570d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... b25f7019ae500fe2ed6713b46b570d
description [clinicaltrials_vocabulary:description]
Patients receive busulfan IV o ...... ver 2 hours on days -3 and -2.
identifier
clinicaltrials_resource:NCT00003816/arm-group/29b25f7019ae500fe2ed6713b46b570d
title
NCT00003816 arm group 29b25f7019ae500fe2ed6713b46b570d
@en
type
label
NCT00003816 arm group 29b25f70 ...... 25f7019ae500fe2ed6713b46b570d]
@en